HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth

Zymeworks Inc. ( ZYME ) has just announced some very positive data from the Phase 3 HERIZON-GEA-01 trial. Specifically, Ziihera, their treatment for HER2-positive gastroesophageal adenocarcinoma, did very well in achieving an overall survival of longer than two years. Now, with this trial data comesI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay developme ...